For decades, families have watched helplessly as Alzheimer’s disease slowly stole their loved ones’ memories, personalities, and independence. Traditional medications could only ease symptoms temporarily while the disease continued its relentless march forward. But today marks a turning point in the fight against Alzheimer’s.

At the Neurology Institute of Huntsville, we’re proud to offer Leqembi and Kisunla treatment for dementia. Leqembi and Kisunla are the first FDA-approved therapies for dementia that target the underlying cause of Alzheimer’s disease.

Understanding Alzheimer’s Disease and Dementia

Before we explore these revolutionary Leqembi infusion therapy for Alzheimer’s and Kisunla infusion therapy for Alzheimer’s treatments, it’s important to understand what we’re fighting against.

What Is Dementia?

Dementia is an umbrella term for a group of symptoms that severely affect memory, thinking, and social abilities, interfering with daily life. Think of it like the word ‘fever’: it describes a symptom that can be caused by many different underlying conditions.

Common types of dementia include:

• Alzheimer’s disease (accounting for 60-80% of cases)
• Vascular dementia
• Lewy body dementia
• Frontotemporal dementia

What Is Alzheimer’s Disease?

Alzheimer’s disease is the most common cause of dementia. It’s a progressive brain disorder caused by the buildup of two abnormal proteins in the brain: amyloid-beta plaques and tau tangles.

These proteins accumulate between and inside nerve cells, disrupting communication and eventually killing brain cells. What makes Alzheimer’s particularly challenging is that these brain changes begin years, even decades, before symptoms appear. By the time memory problems become noticeable, significant damage has already occurred.

Recognizing the Symptoms of Alzheimer’s and Dementia

Early detection is crucial to access new Alzheimer’s disease infusion treatments. Here are 10 warning signs that should prompt a visit to a neurologist:

• Memory loss that disrupts daily life: Forgetting recently learned information, important dates, or repeatedly asking the same questions.
• Challenges in planning or problem-solving: Difficulty following familiar recipes, managing monthly bills, or concentrating on tasks.
• Difficulty completing familiar tasks: Trouble driving to familiar locations, organizing a grocery list, or remembering rules of favorite games.
• Confusion with time or place: Losing track of dates, seasons, or forgetting where they are or how they got there.
• Trouble understanding visual images: Difficulty reading, judging distance, or determining color contrast.
• Problems with words in speaking or writing: Struggling to follow conversations, repeating themselves, or having trouble finding the right words.
• Misplacing things: Putting things in unusual places and being unable to retrace steps to find them.
• Decreased or poor judgment: Poor decision-making with money or neglecting personal grooming.
• Withdrawal from work or social activities: Removing themselves from hobbies, social activities, or work projects.
• Changes in mood and personality: Becoming confused, suspicious, depressed, fearful, or anxious.

Why Traditional Treatments Haven’t Been Enough?

Until recently, Alzheimer’s medications were the standard of care. While these drugs can temporarily help manage symptoms, such as improving memory or reducing confusion, they do nothing to slow the underlying disease process. It’s like treating a fever without addressing the underlying infection.

Traditional treatments couldn’t:

• Remove toxic amyloid plaques from the brain
• Slow the progression of cognitive decline
• Preserve functional independence longer
• Address the root cause of the disease

What Is Leqembi? The First Amyloid-Targeting Therapy for Alzheimer’s

Leqembi infusion therapy for Alzheimer’s (lecanemab) is a monoclonal antibody treatment developed by Eisai and Biogen. FDA-approved in January 2023, it was the first therapy proven to slow cognitive decline in early Alzheimer’s disease.

How Leqembi Works?

Leqembi targets small, soluble clusters of amyloid-beta protein called protofibrils before they form into larger plaques. By binding to and removing toxic protein fragments, Leqembi helps clear the brain of substances that drive Alzheimer’s disease progression. This amyloid-targeting therapy for Alzheimer’s approach attacks the disease at its source.

What Is Kisunla?

Kisunla infusion therapy for Alzheimer’s (donanemab), developed by Eli Lilly and FDA-approved in July 2024, offers a unique approach to mild cognitive impairment Alzheimer’s treatment options.

How Kisunla Works?

Unlike Leqembi, which targets soluble amyloid protofibrils, Kisunla targets the amyloid plaques themselves, the hardened deposits of protein that have already formed in the brain. This amyloid-targeting therapy for Alzheimer’s helps remove existing damage.

What Makes Leqembi and Kisunla Different from All Previous Treatments?

These early Alzheimer’s disease treatments with infusions represent a paradigm shift in how we approach Alzheimer’s care. Here’s what makes them revolutionary:

When to Visit a Neurologist for Dementia?

Early diagnosis is absolutely critical for accessing Leqembi and Kisunla treatment for dementia. These therapies work best in the earliest stages of disease. Schedule a neurologist consultation when:

• Memory loss that disrupts daily life or work performance
• Family history of Alzheimer’s or dementia
• Age 55 or older with mild cognitive changes
• Difficulty with familiar tasks or problem-solving
• Confusion about time, place, or recent events
• Trouble finding words or following conversations
• Changes in judgment or decision-making
• Withdrawal from social activities or hobbies
• Mood or personality changes that concern family members

What to Expect When You Start Leqembi or Kisunla Infusion Treatment in Huntsville?

At the Neurology Institute of Huntsville, we’ve designed our Alzheimer’s infusion therapy options program to make care easier throughout your treatment journey.

Comprehensive Evaluation

Your journey begins with a thorough assessment:

• Medical history review (family history, current medications, and overall health)
• Cognitive testing
• Blood work
• Brain imaging (if needed)

Treatment Planning

• Your provider will discuss the best suitable treatment for you
• Treatment schedule and administration options
• Monitoring requirements (regular MRIs to watch for side effects)
• Insurance coverage and financial assistance programs

Insurance and Cost Management

We understand that navigating insurance can be overwhelming. Our team will:

• Verify your Medicare or private insurance coverage
• Help you understand out-of-pocket costs
• Connect you with pharmaceutical patient assistance programs
• Handle prior authorization and documentation

Trusted Neurology Care in Huntsville

At the Neurology Institute of Huntsville, patients have access to advanced, evidence-based Alzheimer’s treatments, including Leqembi and Kisunla. Our team provides detailed cognitive assessments, imaging confirmation, and structured infusion monitoring for patients who qualify.

Patients are guided every step of the way under the leadership of Dr. Jitesh Kar, MD, MPH, a board-certified neurologist recognized for clinical excellence and patient-centered care. Our providers ensure that patients receive evidence-based, up-to-date treatment aligned with the latest clinical research.

Final Thoughts

For the first time in history, we have treatments that can actually slow the progression of Alzheimer’s disease. Leqembi and Kisunla treatment for dementia represents genuine hope.

But here’s the critical truth: these treatments work best when started early. Research shows that patients who wait too long may lose eligibility altogether as their disease progresses beyond the early stage. The advances in diagnosis, including the new FDA-approved blood test for Alzheimer’s diagnosis, make it easier than ever to detect Alzheimer’s early and start disease-modifying treatment for early Alzheimer’s when it can make the most difference.

FAQs

Q.1  How effective are Leqembi and Kisunla for treating Alzheimer’s?

Ans: Both the Leqembi and Kisunla cause slow cognitive decline. preserving independence for years longer than untreated Alzheimer’s disease.

Q2. Are these treatments covered by Medicare and insurance?

Ans: Yes. Medicare covers both with registry participation. Most private insurance plans also provide coverage. Kindly connect with your provider for more details.

Q3. What are the main side effects of Alzheimer’s infusion therapy?

Ans: Most common side effects include: infusion reactions and ARIA (brain swelling/microbleeds), monitored via MRI. Usually mild and manageable.

Q4. Can I get the new Alzheimer’s blood test in Huntsville?

Ans: Yes. FDA-approved blood tests are available at Neurology Institute of Huntsville, offering less invasive diagnosis than PET scans.

Q5. How long does Alzheimer’s infusion treatment take?

Ans: Each infusion takes about 1 hour plus observation time. Leqembi offers at-home maintenance injections after 18 months.

Q6. What’s the difference between Leqembi and Kisunla treatments?

Ans: Leqembi targets early protein clusters; Kisunla targets formed plaques. Kisunla may be time-limited; Leqembi offers at-home dosing.